These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 9098190)
1. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. Taki J; Sumiya H; Tsuchiya H; Tomita K; Nonomura A; Tonami N J Nucl Med; 1997 Apr; 38(4):501-6. PubMed ID: 9098190 [TBL] [Abstract][Full Text] [Related]
2. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of bone and soft tissue lesion using 99mTc-MIBI: comparison with 201Tl and the relation to chemotherapeutic effect]. Sumiya H; Taki J; Tonami N; Asada N; Tsuchiya H; Tomita K Kaku Igaku; 1997 Feb; 34(2):105-11. PubMed ID: 9095573 [TBL] [Abstract][Full Text] [Related]
4. Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Tl-201 imaging. Taki J; Higuchi T; Sumiya H; Tsuchiya H; Minato H; Tomita K; Tonami N J Orthop Res; 2008 Mar; 26(3):411-8. PubMed ID: 17960652 [TBL] [Abstract][Full Text] [Related]
5. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Moustafa H; Riad R; Omar W; Zaher A; Ebied E Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955 [TBL] [Abstract][Full Text] [Related]
6. Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors. Sumiya H; Taki J; Tsuchiya H; Nonomura A; Miyauchi T; Tonami N J Nucl Med; 1998 Sep; 39(9):1600-4. PubMed ID: 9744351 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors. Wakabayashi H; Taki J; Inaki A; Sumiya H; Zen Y; Tsuchiya H; Kinuya S Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020 [TBL] [Abstract][Full Text] [Related]
9. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. Caner B; Kitapçl M; Unlü M; Erbengi G; Calikoğlu T; Göğüş T; Bekdik C J Nucl Med; 1992 Mar; 33(3):319-24. PubMed ID: 1531501 [TBL] [Abstract][Full Text] [Related]
10. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours. Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180 [TBL] [Abstract][Full Text] [Related]
11. Evaluating benign and malignant musculoskeletal lesions with radionuclide angiography and SPECT using Tc-99m MIBI. Ishiyama K; Tomura N; Okada K; Nagasawa H; Sashi R; Sasaki K; Sato K; Watarai J Clin Nucl Med; 2005 Sep; 30(9):598-603. PubMed ID: 16100476 [TBL] [Abstract][Full Text] [Related]
13. Quantitative planar imaging with technetium-99m methoxyisobutyl isonitrile: comparison of uptake patterns with thallium-201. Sinusas AJ; Beller GA; Smith WH; Vinson EL; Brookeman V; Watson DD J Nucl Med; 1989 Sep; 30(9):1456-63. PubMed ID: 2671298 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of TI-201 and three-phase bone scintigraphy for bone and soft-tissue tumors. Nishiyama Y; Yamamoto Y; Toyama Y; Satoh K; Ohkawa M; Tanabe M Clin Nucl Med; 2000 Mar; 25(3):200-5. PubMed ID: 10698418 [TBL] [Abstract][Full Text] [Related]
15. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293 [TBL] [Abstract][Full Text] [Related]
16. Comparative radionuclide imaging of metastatic insular carcinoma of the thyroid: value of technetium-99m-(V)DMSA. Yen TC; King KL; Yang AH; Liu RS; Yeh SH J Nucl Med; 1996 Jan; 37(1):78-80. PubMed ID: 8544007 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. Yamamoto Y; Nishiyama Y; Satoh K; Takashima H; Ohkawa M; Fujita J; Kishi T; Matsuno S; Tanabe M J Nucl Med; 1998 Sep; 39(9):1626-9. PubMed ID: 9744357 [TBL] [Abstract][Full Text] [Related]
18. Hexakis (2-methoxy isobutylisonitrile) technetium-99m and thallium-201 chloride: uptake and release in cultured myocardial cells. Maublant JC; Gachon P; Moins N J Nucl Med; 1988 Jan; 29(1):48-54. PubMed ID: 3335927 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Ugur O; Kostakğlu L; Güler N; Caner B; Uysal U; Elahi N; Haliloğlu M; Yüksel D; Aras T; Bayhan H; Bekdik C Eur J Nucl Med; 1996 Oct; 23(10):1367-71. PubMed ID: 8781142 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Tc-99m MIBI and Tl-201 uptake in musculoskeletal lesions. Adalet I; Ozger H; Cantez S Clin Nucl Med; 1996 Feb; 21(2):118-21. PubMed ID: 8697680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]